Charles Moore,  —

Charles Moore is a syndicated columnist for several major Canadian print newspapers and the Science and Research Section editor for CF News Today.

Articles by Charles Moore

“Laser Trapping” Technique Could Lead To Better Management of Bacterial Infections in CF Patients

In a report published this week by SPIE — an international not-for-profit society serving more than 256,000 constituents from approximately 155 countries advancing an interdisciplinary approach to the science and application of light — entitled “Laser trapping to show the effects of bacterial arrangement on biofilm infection” (30 December 2014,…

Cystic Fibrosis Patients Respond Well to Unique Antibacterial Ceragenins

Two recently published reviews in peer-reviewed journals plus another study highlight the potential utility of ceragenins or cationic selective antimicrobials (CSAs) — a proprietary, patented, first-in-class small molecule technology platform for fighting bacterial infections, such as pulmonary infections associated with cystic fibrosis (CF) and hospital acquired infections associated with…

UNM And Avisa Pharma Developing Fast, Inexpensive, Breathalyzer Test For CF, TB, HCAP, VAP, And Other Lung Infections

Santa Fe, New Mexico based startup Avisa Pharma Inc. is a clinical stage company established in 2010 to develop and commercialize a new technology invented by Dr. Graham Timmins, Avisa’s Co-founder/Chief Science Officer and a University of New Mexico College of Pharmacy Associate Professor, who was assisted by colleagues from UNM’s School…

FDA Advisory Committee Gives Cystic Fibrosis Drug Kalydeco (ivacaftor) Thumbs-Up for Patients Six And Up With R117H Mutation

Vertex Pharmaceuticals Incorporated announced Tuesday that the U.S. Food and Drug Administration’s Pulmonary Allergy Drugs Advisory Committee (PADAC) voted 13-2 to recommend approval of Kalydeco (ivacaftor) in people with cystic fibrosis (CF) ages six and older who have the R117H mutation in the cystic fibrosis transmembrane regulatory (CFTR) gene,…